X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PIRAMAL ENTERPRISES ASTRAZENECA PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 408.9 7.7 5,315.2% View Chart
P/BV x 20.0 1.4 1,452.6% View Chart
Dividend Yield % 0.0 1.2 -  

Financials

 ASTRAZENECA PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
PIRAMAL ENTERPRISES
Mar-18
ASTRAZENECA PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,2853,083 41.7%   
Low Rs6341,902 33.3%   
Sales per share (Unadj.) Rs189.6589.7 32.1%  
Earnings per share (Unadj.) Rs-0.2284.0 -0.1%  
Cash flow per share (Unadj.) Rs3.8310.5 1.2%  
Dividends per share (Unadj.) Rs025.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs68.61,467.0 4.7%  
Shares outstanding (eoy) m25.00180.27 13.9%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x5.14.2 119.7%   
Avg P/E ratio x-4,712.78.8 -53,702.4%  
P/CF ratio (eoy) x249.68.0 3,109.2%  
Price / Book Value ratio x14.01.7 822.7%  
Dividend payout %08.8 0.0%   
Avg Mkt Cap Rs m23,988449,332 5.3%   
No. of employees `0001.66.8 22.8%   
Total wages/salary Rs m1,60519,881 8.1%   
Avg. sales/employee Rs Th3,040.215,535.6 19.6%   
Avg. wages/employee Rs Th1,029.22,905.4 35.4%   
Avg. net profit/employee Rs Th-3.37,482.5 -0.0%   
INCOME DATA
Net Sales Rs m4,740106,310 4.5%  
Other income Rs m922,595 3.5%   
Total revenues Rs m4,832108,906 4.4%   
Gross profit Rs m-13051,599 -0.3%  
Depreciation Rs m1014,773 2.1%   
Interest Rs m029,783 0.0%   
Profit before tax Rs m-13919,638 -0.7%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5-28,764 -0.0%   
Profit after tax Rs m-551,203 -0.0%  
Gross profit margin %-2.748.5 -5.6%  
Effective tax rate %-3.7-146.5 2.5%   
Net profit margin %-0.148.2 -0.2%  
BALANCE SHEET DATA
Current assets Rs m2,726118,154 2.3%   
Current liabilities Rs m2,435462,260 0.5%   
Net working cap to sales %6.1-323.7 -1.9%  
Current ratio x1.10.3 438.1%  
Inventory Days Days7427 277.5%  
Debtors Days Days4147 87.6%  
Net fixed assets Rs m1,035113,727 0.9%   
Share capital Rs m50361 13.9%   
"Free" reserves Rs m942264,093 0.4%   
Net worth Rs m1,716264,454 0.6%   
Long term debt Rs m0242,206 0.0%   
Total assets Rs m4,156726,834 0.6%  
Interest coverage xNM1.7-  
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x1.10.1 779.7%   
Return on assets %-0.111.1 -1.1%  
Return on equity %-0.319.4 -1.5%  
Return on capital %010.3 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m37515,110 2.5%   
Fx outflow Rs m4704,298 10.9%   
Net fx Rs m-9610,813 -0.9%   
CASH FLOW
From Operations Rs m-8-159,666 0.0%  
From Investments Rs m-146-17,677 0.8%  
From Financial Activity Rs m862186,503 0.5%  
Net Cashflow Rs m7099,364 7.6%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.0 7.5%  
FIIs % 15.7 26.6 59.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 16.5 55.2%  
Shareholders   12,856 93,274 13.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   TORRENT PHARMA  ALKEM LABORATORIES  AJANTA PHARMA  PFIZER  ALEMBIC PHARMA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open on a Positive Note; Realty & Auto Stocks Lead(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.2% while the Hang Seng is up 1.6%.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Dec 12, 2018 11:49 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS